New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
Midostaurin was granted a priority review for a new drug application by the FDA to treat a subset of patients with acute myeloid leukemia. Midostaurin (PKC412) was granted a priority review to a new ...
There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation. Patients who ...
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback